PRCT Stock Forecast & Price Target

PROCEPT BioRobotics demonstrated a positive trajectory in its operations, with handpiece utilization growing at an average of approximately 6.1% per quarter over the past six quarters, signaling increasing demand for its urologic surgical systems. The company has strategically focused on curtailing operating expense growth to half of top-line growth, suggesting a focused pathway toward improved profitability that has resonated positively with investors. Furthermore, management reported strong visibility into its growth pipeline, predicting record quarterly system placements in Q4, with 58 new systems placed during the quarter, outperforming previous guidance despite a slightly softened macroeconomic environment.

PROCEPT BioRobotics has experienced a significant decline in its stock, with shares down approximately 54% year-to-date, indicating a trend of disappointing results despite the company's ability to exceed its own projections. The company faces several downside risks that could impact future performance, including a potential decline in demand for capital equipment, reduced usage of handpieces by customers, heightened competitive pressure, and potential changes in reimbursement policies for its Aquablation therapy. Furthermore, the consensus estimates for 2026 sales may be revised downward, as investors remain concerned about utilization rates and inventory levels, likely contributing to the ongoing negative sentiment surrounding the stock.